This clinical trial aimed at evaluating changes in neuropsychiatric scales for depression, anxiety, insomnia, and sleep quality in people living with HIV (PLHIV) who initiate antiretroviral therapy (ART) with a regimen of Dolutegravir (DTG) or Darunavir/Cobicistat (DRV/c), both combined with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
Patients living with HIV not experienced to ART
Age ≥ 18 years.
eGFR >60 mL/min
Beneficiaries of the Mexican Social Security Institute treated at the "La Raza" National Medical Center
Patients with use of antidepressants/anxiolytics prior to starting ART
Any Contraindication for the use of second generation INSTI or IP ART regimen
Coinfection with Hepatitis C Virus
Known resistance mutations to any of the components of both treatment regimens.